Oruka Therapeutics, Inc. cotiza a 82.11 USD y tiene una capitalización bursátil de $5.4B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for t…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.55 | $-0.48 | $-0.45 |
| Estimado | $-0.62 | $-0.50 | $-0.54 | $-0.62 |
| Sorpresa | — | -10.0% | +11.1% | +27.4% |
| Métrica | ORKA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -22.3% | -40.4% | +18.1% |
| ROA | -21.6% | -32.0% | +10.4% |
| Current Ratio | 22.37 | 2.84 | +19.53 |
| Debt / Equity | — | 0.28 | — |